Toxicogenomics-2015 is a remarkable event which brings together a unique and International mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions making the Symposium a perfect platform to share experience, foster collaborations across industry and academia, and evaluate emerging technologies across the globe.

Toxicogenomics-2015 anticipates more than 600 thought provoking presentations and eminent Keynote lectures. The attending delegates include Editorial Board Members of featured OMICS Group Journals. This is an excellent opportunity for the participants from Universities, Institutes and other Private Organizations to interact with the World class Scientists and renowned speakers.

The global Toxicogenomics market is estimated to reach $17,227 million by 2018 at a CAGR of 13.5% during the forecast period (2013–2018). The market will witness a double-digit growth attributed to the increasing acceptance of in vitro methods over in vivo ones. Government support to stop animal testing, new and promising technologies, and advancement in new approaches are significant factors forcing the market in the forecast period. Initiation of Tox 21, government programs by the U.S. government and growing number of drug discoveries and innovations globally represent an opportunity for the growth of the market.

Detection of the toxic effects much earlier in the development stage, the pharmaceutical industry adapted to in vitro methods apart from the rising pressure to reduce the drug attrition rates to control the drug development costs and time line. The pharmaceutical industry has been witnessing a enormous growth as a result of government initiatives such as AXLR8 program that was initiated by the European Union. Geographic analysis reveals that Europe was the largest contributor to the global Toxicogenomics market in 2013. It will also be the fastest growing region till 2018.